Companies:
50,753
Total Market Cap:
150445247079911.02
Global Rank
#4577
Country Rank
#49
Market Cap
3.46 B
Price
30.7
Change (%)
4.56%
Volume
1.31 M
NewAmsterdam Pharma Company N.V.'s latest marketcap:
3.46 B
As of 10/02/2025, NewAmsterdam Pharma Company N.V.'s market capitalization has reached $3.46 B. According to our data, NewAmsterdam Pharma Company N.V. is the 4577th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.46 B |
| Revenue (ttm) | 64.01 M |
| Net Income (ttm) | -165,715,000 |
| Shares Out | 112.63 M |
| EPS (ttm) | -1.55 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/05/2025 |
Market Cap Chart
Data Updated: 10/02/2025
NewAmsterdam Pharma Company N.V.'s yearly market capitalization.
NewAmsterdam Pharma Company N.V. has seen its market value grow from $139.43 M to $3.46 B since 2021, representing a total increase of 2,379.79% and an annual compound growth rate (CAGR) of 135.10%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 10/02/2025 | $3.46 B | 16.42% | 4577 |
| 12/31/2024 | $2.75 B | 199.19% | 4625 |
| 12/29/2023 | $919.56 M | 3.44% | 9125 |
| 12/30/2022 | $889 M | 537.58% | 8885 |
| 12/31/2021 | $139.43 M | 21007 |
Company Profile
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company dedicated to advancing therapies that improve patient care for those with metabolic diseases.
Key Focus Areas
- Obicetrapib Development: An oral low-dose cholesteryl ester transfer protein (CETP) inhibitor currently in clinical trials.
- Cardiovascular Disease Treatment: Evaluated as both a monotherapy and in combination with ezetimibe to lower LDL-C levels.
- Alzheimer’s Disease Research: Phase 2a clinical trials underway for Obicetrapib’s potential application in Alzheimer’s treatment.
Company Headquarters
Based in Naarden, the Netherlands, NewAmsterdam Pharma is committed to pioneering innovative therapies for metabolic and related diseases.
Frequently Asked Questions
-
What is NewAmsterdam Pharma Company N.V.'s (NAMS) current market cap?As of 10/02/2025, NewAmsterdam Pharma Company N.V. (including the parent company, if applicable) has an estimated market capitalization of $3.46 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does NewAmsterdam Pharma Company N.V. (NAMS) rank globally by market cap?NewAmsterdam Pharma Company N.V. global market capitalization ranking is approximately 4577 as of 10/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.